ABcann Launches Beacon Medical
May 23 2018 - 7:00AM
ABcann Global Corporation (TSX-V:ABCN)
(“
ABcann” or the “
Company”) is
pleased to announce the launch of Beacon Medical, its new medical
cannabis brand. The goal of Beacon Medical is
to help patients and their healthcare
providers navigate the complex medical cannabis market to find
the best treatment option.
“Our vision is to leverage our unique
experience in the global pharmaceutical industry to create one of
the most respected medical cannabis companies. The launch of Beacon
is an important step towards that vision,” stated Barry Fishman,
Chief Executive Officer.
The adoption of the Beacon Medical brand is a
direct result of an exclusive study of 1,500 Canadians that ABcann
conducted in early 2018. The Company is committed to developing its
brands based on deep consumer insights. ABcann’s study identified
that 73% of adult Canadians who are not currently using cannabis,
but have a treatable condition, say they lack the appropriate
knowledge of how to use medical cannabis, and 67% say they are
unfamiliar with how to obtain medical cannabis. With so many
Canadians not clear about how to obtain and use medical cannabis,
ABcann believes the market is ready for a brand that makes the
process easier to navigate.
Beacon Medical will differentiate itself by
focusing on the patient experience: simple registration and product
classification, efficient purchasing, pharmaceutical-grade
products, and compassionate customer service.
“A beacon is a symbol of hope and relief
for those seeking guidance, and that’s why Beacon is a perfect
metaphor and the ideal name for our new medical cannabis brand. We
want to develop simple ways to help people navigate the complex
world of cannabis,” stated Sung Kang, Chief Marketing
Officer.
Beacon Medical invites investors, media and
consumers to get a first glimpse of the new Beacon brand at the
Lift Expo taking place in Toronto from May 25th to 27th, 2018. The
full Beacon Medical website and product line, which will include
the introduction of cannabis oils, will be available to ACMPR
patients by early summer 2018.
About ABcann
ABcann is recognized for high-quality, trusted
products and services. It holds production and sales licenses from
Health Canada, and its flagship facility in Napanee, Ontario
contains proprietary plant-growing technology, centred on its
specially designed, environmentally-controlled growing chambers.
This approach results in the production of pharmaceutical-grade
cannabis products. ABcann is expanding its production capacity and
pursuing partnership and product development opportunities
domestically, as well as in select international markets, such as
Germany, Australia and Israel.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer for Forward-Looking
Information
Certain statements in this news release may be
considered forward-looking statements, which are statements that
are not purely historical, including statements regarding the
beliefs, plans, expectations or intentions of ABcann and its
management regarding the future. Forward-looking statements in this
news release include statements relating to: the expected
legalization of the adult-use cannabis market; the expected launch
time of the Beacon Medical product line and website; the expected
impact of the Beacon Medical brand on the market; the Beacon
Medical product line including cannabis oils; and ABcann’s goal of
becoming one of the best and most respected medical cannabis
business in Canada and internationally. Such statements are subject
to risks and uncertainties that may cause actual results,
performance or developments to differ materially from those
contained in the forward-looking statements, including the
possibility that ABcann may not derive the expected benefits from
the adoption of the Beacon Medical brand; that the market will not
adopt the Beacon Medical brand; that the differentiating factors
between the Beacon Medical product line and those of ABcann’s
competitors will not materialize; that the adult-use market will
not open as expected; and other factors beyond the Company’s
control. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them.
Readers are urged to consider these factors, and the more extensive
risk factors included in the Company’s annual information form
dated April 30, 2018, which is available on SEDAR, carefully in
evaluating the forward-looking statements contained in this news
release, and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety
by these cautionary statements. The forward-looking statements in
this news release are made as of the date hereof and the Company
disclaims any intent or obligation to update publicly any such
forward-looking statements, whether because of new information,
future events or results or otherwise, except as required by
applicable securities laws.
For more information about ABcann, please contact:
Barry Fishman at barry.fishman@abcannglobal.com or
Michael Bumby at michael.bumby@abcannglobal.com
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Sep 2023 to Sep 2024